Connect with us

Research

NIHR Dementia TRC appoints new leaders

Published

on

The incoming chair of an internationally renowned, UK-based dementia research network has said it is critical experts “seize the moment” and pool their knowledge to enhance patients’ chances and accelerate the launch of new treatments.

Dr Catherine Mummery is set to take over the helm of the National Institute for Health and Care Research (NIHR) Dementia Translational Research Collaboration (D-TRC).

Joining her as joint deputy chairs at the alliance will be NIHR Newcastle’s Biomedical Research Centre theme lead, Professor John-Paul Taylor, and Dr Vanessa Raymont, director of research and development at Oxford Health NHS Foundation Trust.

The new leaders will spearhead the next five years of clinical dementia research development and delivery, bringing together top experts in the field and guiding pioneering translational exploration into the syndrome – a key part of the Dame Barbara Windsor Dementia Mission launched in August 2022 in the late actresses memory to speed up the growth of treatments and contribute to the Government’s goal of doubling funding to £160m by 2024/25.

Dr Catherine Mummery

Speaking about her appointment Dr Mummery, who leads the cognitive disorders service at the National Hospital for Neurology and Neurosurgery in London, and is head of novel therapeutics at the Dementia Research Centre at UCL, said: “This presents a unique and timely opportunity to make the UK a global leader in early phase clinical trials in dementia.

“We are entering a new era in potential treatments for AD and other diseases. It is critical we seize the moment and come together as a community to speed up therapies and optimise chances for our patients.”

The D-TRC works within the national network of NIHR Biomedical Research Centres, along with clinical research facilities and members of the devolved nations. The new leadership team will also collaborate with the charities Alzheimer’s Society and Alzheimer’s Research UK.

Dr Mummery will be taking over from Professor David Burn, the Pro-Vice-Chancellor of the Faculty of Medical Sciences at Newcastle University, who has been critical in building momentum and galvanising the D-TRC over the last 12 months by leveraging research-related grant funding. During that time £7.17m has been channelled by the D-TRC into new dementia research.

Professor Burn, who has an international reputation for research in dementia associated with Parkinson’s, provided expert input into the All Parliamentary Group on Dementia. He also offered his expert advice to the Department of Health and Social Care on the ‘Dementia Moonshot,’ the British Government’s 10-year plan to increase funding to tackle the syndrome, which currently affects around 900,000 people in the UK.

UK patient numbers are expected to exceed one million by 2030 and 1.6 million by 2050.

Professor John-Paul Taylor

Professor Taylor comes to his role as joint deputy chair having published over 200 peer reviewed articles and edited two books in the field of dementia and old age psychiatry. Currently acting as the chief investigator for the NIHR HTA COBALT trial assessing the clinical and cost-effectiveness of memantine in patients with dementia and Parkinson’s disease, he said creating a pathway for people living with an ongoing decline of brain functioning to take part in observational assessments, is important to him.

“At the moment, approximately less than one in 100 people living with dementia take part in dementia clinical trials in the UK. Addressing this challenge is critical to discovering new and effective treatments.

“As joint deputy chair of the Dementia TRC, I am immensely excited that I can contribute to this fantastic initiative. It means that, at scale, we will be able to offer many more people living with dementia the opportunity to take part in meaningful clinical trials.”

Dr Raymont added: “Being appointed to the role of joint deputy chair of the Dementia TRC is a huge honour. Looking back on my experience of dementia research over the last 30 years, this is truly an exciting time.

“I look forward to working with my colleagues in the Dementia TRC and beyond, to bring the amazing infrastructure we have in the UK together to further clinical trials.”

Dr Vanessa Raymont

Dr Richard Oakley, associate director of research at Alzheimer’s Society said he welcomed the new appointments and “the increase in investment that this vital piece of the UK clinical trial infrastructure is going to receive.

“The benefits of hosting clinical trials are convincing. In 2019, the total estimated income for the NHS from delivering commercial clinical trials across all disease areas was £355m.

“A growing industry pipeline in dementia means this is an area of huge opportunity for UK clinical research. We are at a turning point in the fight against dementia. Now is the time to invest in clinical research.”

Dr Oakley’s support for the appointment has been echoed by David Thomas, head of policy at Alzheimer’s Research UK. He said: “We are delighted that Cath, John-Paul and Vanessa are taking on these roles. I know that they have the skills and experience to maximise this opportunity. They will aim to raise the UK’s profile in dementia clinical research on a global stage. We look forward to working with them on this important agenda.

“There is an urgent need to futureproof the UK’s clinical trial capacity and infrastructure. This is essential for attracting industry investment to the UK and increasing the number of people with dementia who take part in trials.”

Research

Older adults hospitalised for heart failure had high risk of kidney complications, finds study

Published

on

In a study of Medicare beneficiaries, researchers from Brigham and Women’s Hospital found that one year after hospitalisation for heart failure, six per cent of patients had progressed to dialysis.

Researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, have found links between heart failure and kidney disease that support new approaches for integrating the care of these conditions.

In an analysis that included adults ages 65 and older who were hospitalised for heart failure from across 372 sites in the US, researchers found that patients had a substantial risk of kidney complications, with approximately six per cent progressing to dialysis within a year of being hospitalised for heart failure. The new results are published in JAMA Cardiology.

“We know that heart and kidney health are highly interconnected, but management of heart and kidney disease remains relatively siloed, and kidney health often isn’t prioritised in patients with heart disease until advanced stages,” said first author John Ostrominski, MD, a fellow in Cardiovascular Medicine and Obesity Medicine at the Brigham.

“Declining kidney function is often asymptomatic until late in the disease course, but even less advanced stages of kidney impairment can have important implications for cardiovascular health. Hence, there’s a need for analyses that assess kidney outcomes in people with heart failure.”

About two thirds of older adults with heart failure have abnormal kidney function. However, few analyses to date have investigated the occurrence of clinically relevant kidney outcomes, such as hospitalisation for acute kidney injury or dialysis, in patients with heart failure.

Evaluating these more recognisable and patient-centered outcomes, according to Ostrominski, may result in substantial changes to the way that heart and kidney disease are managed together in the clinic.

The study analysed Medicare claims data from 85,298 patients over the age of 65 who were hospitalised with heart failure between 2021 and 2024. The data was sourced from the Get with the Guidelines-Heart-Failure Registry, an initiative supported by the American Heart Association that seeks to connect hospitals with current evidence-based guidelines and accurate measurement tools to improve care quality and industry practices. The registry is also proving a valuable source of information for researchers examining trends in health outcomes for patients with heart failure.

In the present study, 63 percent of patients were discharged with significantly impaired kidney function, as measured by their rate of filtration. The researchers also found that the risk of adverse kidney outcomes increased steeply in patients with lower kidney function. By one year after discharge, six per cent of patients were on dialysis, and seven per cent of patients were either on dialysis or had progressed to end stage kidney disease.

The findings suggest that at the individual provider level, cardiologists should prioritise assessing kidney function – including measuring kidney filtration and looking for evidence of protein in the urine, also known as albuminuria – in all patients with heart failure, and, when indicated, consider heart therapies that are known to improve kidney outcomes.

More broadly, the study emphasises the need for systemic changes that better support the simultaneous management of heart and kidney disease, including establishing clinics focused on integrating these two care areas, incorporating kidney outcomes into health care performance metrics for cardiovascular diseases, and expanding Medicare reimbursement protocols for interdisciplinary chronic care management.

Researchers at Mass General Brigham are actively engaged as sites for clinical trials evaluating newer treatment strategies for individuals with cardiovascular and kidney disease. The Accelerator for Clinical Transformation team is also developing new ways of delivering care—including medications with established kidney benefits—to eligible patients with and without heart failure.

“The trends we’ve observed aren’t especially surprising given what we know about the links between heart and kidney health, but what’s important is that this research emphasises the scope of the problem and gives us information we can act upon to directly improve clinical outcomes in patients with heart failure,” said Ostrominski.

“There are important opportunities for patients and providers, healthcare institutions, and, at the broader state and national levels, in terms of healthcare policy that could make a big difference for patients.”

Continue Reading

Research

Heart healthy behaviours may help reverse rapid cell aging – study

Published

on

The benefits gained with higher lifestyle scores may be associated with the positive influence of heart disease risk factors on the aging of the body and its cells, finds a new study.

The benefit of better heart health may be associated with the positive impact of heart healthy lifestyle factors on biological aging (the age of the body and its cells), according to new research published in the Journal of the American Heart Association.

According to the American Heart Association’s 2024 Heart Disease and Stroke Statistics, heart disease and stroke claimed more lives in the US in 2021 than all forms of cancer and chronic lower respiratory disease combined, and also accounted for approximately 19.91 million global deaths.

This study analysed whether a chemical modification process known as DNA methylation, which regulates gene expression, may be one mechanism by which cardiovascular disease health factors affect cell aging and the risk of death.

DNA methylation levels are the most promising biomarker to estimate biological age. To some degree, biological age is determined by your genetic makeup, and it can also be influenced by lifestyle factors and stress.

Researchers examined health data for 5,682 adults (mean age of 56 years; 56% of participants were women) who were enrolled in the Framingham Heart Study, an ongoing, large, multigenerational research project aimed at identifying risk factors for heart disease.

Using interviews, physical exams and laboratory tests, all participants were assessed using the American Heart Association’s Life’s Essential 8 tool. The tool scores cardiovascular health between 0-100 (with 100 being the best) using a composite of four behavioral measures (dietary intake, physical activity, hours slept per night and smoking status) and four clinical measurements (body mass index, cholesterol, blood sugar and blood pressure).

Each participant was also assessed using four tools that estimate biological age based on DNA methylation and a fifth tool that assesses a person’s genetic tendency towards accelerated biological aging. Participants were followed for 11-14 years for new-onset cardiovascular disease, cardiovascular death or death from any cause.

The analysis found:

  • For each 13-point increase in an individual’s Life’s Essential 8 score, the risk of developing cardiovascular disease for the first time was reduced by about 35 per cent death from cardiovascular disease was reduced by 36 per cent and death from any cause was reduced by 29 per cent.
  • In participants with a genetic risk profile making them more likely to have an accelerated biological age, the Life’s Essential 8 score had a larger impact on outcomes potentially via DNA methylation, i.e., DNA methylation accounted for 39 pre cent, 39 per cent, and 78 per cent reduction in the risk of cardiovascular disease , cardiovascular death and all-cause death, respectively.
  • Overall, about 20 per cent of the association between Life’s Essential 8 scores and cardiovascular outcomes was estimated to be due to the impact of cardiovascular health factors on DNA methylation; in contrast, for participants at higher genetic risk, the association was almost 40 per cent.

Jiantao Ma, PhD, senior study author and an assistant professor in the division of nutrition epidemiology and data science at the Friedman School of Nutrition Science and Policy at Tufts University in Boston, said: “While there are a few DNA methylation-based, biological age calculators commercially available, we don’t have a good recommendation regarding whether people need to know their epigenetic age.

“Our message is that everyone should be mindful of the eight heart disease and stroke health factors: eat healthy foods; be more active; quit tobacco; get healthy sleep; manage weight; and maintain healthy cholesterol, blood sugar and blood pressure levels.”

Randi Foraker, Ph.D., M.A., FAHA, co-author of the Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health, said the findings are consistent with prior research.

“We know that modifiable risk factors and DNA methylation are independently associated with cardiovascular disease. What this study adds is that DNA methylation may serve as a mediator between risk factors and cardiovascular disease,” said Foraker, who is a professor of medicine at the Institute for Informatics, Data Science and Biostatistics and director of the Center for Population Health Informatics, both at Washington University School of Medicine in St. Louis, Missouri.

“The study highlights how cardiovascular health can impact biological aging and has important implications for healthy aging and prevention of cardiovascular disease and potentially other health conditions.”

As the study is an analysis of previously collected health data, it cannot prove a cause-and-effect relationship between cardiovascular health risk factors and DNA methylation.

In addition, DNA methylation measures were  from a single time point, which limits the validity of the mediation effect. The study’s findings are also limited because the participants were predominantly of European ancestry, so the interactions of Life’s Essential 8 and genetic aging found in this study may not be generalizable to people of other races or ethnicities.

“Currently, we are expanding our research to include people of other racial and ethnic groups to further investigate the relationship of cardiovascular risk factors and DNA methylation,” Ma said.

Continue Reading

Research

€37.5 million for regenerative medicine using smart materials

Published

on

A new collaboration has received €37.5 million for regenerative medicine using smart materials to help boost research aiming to cure chronic diseases in an ageing population.

The DRIVE-RM consortium has been awarded the funding under the prestigious NWO SUMMIT programme.

The DRIVE-RM, led by Professor of Experimental Nephrology Marianne Verhaar from UMC Utrecht, collaboration involves UMC Utrecht, Utrecht University, Eindhoven University of Technology, Maastricht University, and the Hubrecht Institute, focusing on smart materials that assist the body in healing.

Regenerative medicine involves repairing or replacing damaged tissues and organs by leveraging the body’s own healing processes. DRIVE-RM specifically focuses on material-driven regeneration, using intelligent, lifelike, or even living materials that can prompt the human body to generate new tissue. This approach could radically change the treatment of chronic diseases such as kidney failure, heart failure, and worn joints in the future.

Verhaar commented: “Over the past 20 years, we have established strong collaborative efforts in regenerative medicine in the Netherlands with several large, innovative, and successful projects like the MDR Gravitation consortium. The SUMMIT grant is a wonderful recognition of this work and underscores the importance of regenerative medicine as a leading field in the Netherlands.”

The involved institutes have been collaborating for some time, resulting in valuable innovations. One example is a synthetic, biodegradable blood vessel that aids the body in regenerating blood vessels.

“With the consortium, we developed a blood vessel made of a degradable material that is gradually replaced by the body’s own tissue,” said Verhaar. “It can function immediately as a blood vessel and does not lose functionality as the body takes over. This innovation beautifully combines biology and technology. Now, we will see if it also works well in patients.”

DRIVE-RM is led by five outstanding scientists, all experienced in leading innovative research projects. In addition to Marianne Verhaar, who focuses on kidney and vascular regeneration, the team contains Carlijn Bouten (TU/e, cardiovascular regeneration and tissue technology), Jos Malda (Utrecht University and UMC Utrecht, biofabrication and bone/cartilage regeneration), Jeroen Bakkers (Hubrecht Institute and UMC Utrecht, regenerative biology and heart regeneration), and Clemens van Blitterswijk (Maastricht University, tissue technology and biomaterials).

The DRIVE-RM project takes a multidisciplinary approach, integrating for example Utrecht innovations such as organoids and 4D bioprinting with the technical and material expertise of TU/e and Maastricht University. This leads to new insights in directing repair processes from the level of individual cells to whole organs. These combinations are essential for customising treatments tailored to individual patients and their specific conditions.

A new approach is needed

The number of people with chronic diseases is increasing significantly, mainly due to aging populations. This leads to human suffering and high healthcare costs.

“Regenerative medicine offers a promising opportunity to effectively treat chronic conditions by encouraging the body to heal itself,” continued Verhaar.

“Our scientists aim to fully understand the repair processes of tissues and organs in the patient and then direct this with implantable smart materials.”

The DRIVE-RM consortium focuses on developing new treatments for heart failure, kidney failure, and disorders of bones, cartilage, and joints.

“Besides advancing scientific research and technological innovation, DRIVE-RM also provides a platform for collaboration with clinicians to make the translation to clinical practice,” added Verhaar, “and with ethicists to address ethical issues surrounding regenerative therapies.”

Together with the involved Health Technology Assessment experts, this provides a framework that ensures these advanced interventions remain affordable and accessible.

Enabling future generations of scientists

The DRIVE-RM consortium places great emphasis on maintaining a healthy, inclusive, and diverse research culture and training the next generation—a key goal of the SUMMIT program. Therefore, the team explicitly includes emerging talents who will continue to strengthen Dutch research in regenerative medicine.

Verhaar concludes, “Ultimately, DRIVE-RM is more than just a research initiative; it is a vision for the future of healthcare. A future in which chronic diseases can truly be cured. By collaborating with leading academic institutions, DRIVE-RM aims to make these visionary treatments a reality.”

Continue Reading

Trending